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license (http://creativeassessment, reliable estimates of structural changes in specific brain regions, that could be contrasted
against normal brain aging and inform diagnosis, are lacking. This study aimed to systematically re-
view the literature reporting on MCI-related brain changes.
Methods: The MEDLINE database was searched for studies investigating longitudinal structural
changes in MCI. Studies with compatible data were included in the meta-analyses. A qualitative re-
view was conducted for studies excluded from meta-analyses.
Results: The analyses revealed a 2.2-fold higher volume loss in the hippocampus, 1.8-fold in the
whole brain, and 1.5-fold in the entorhinal cortex in MCI participants.
Discussion: Although the medial temporal lobe is likely to be more vulnerable to MCI pathology,
atrophy in this brain area represents a relatively small proportion of whole brain loss, suggesting
that future investigations are needed to identify the source of unaccounted volume loss in MCI.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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AlthoughAlzheimer’s disease (AD)wasfirst characterized
more than 100 years ago, little concrete progress has been
made toward an effective cure of this progressive disorder.
Identification of mild cognitive impairment (MCI) as a pro-
dromal phase of AD has raised hopes of the possibility of pre-
venting or modifying progressive neurodegeneration in AD.
Indeed, initial attempts at early therapeutic interventions
have reported some successes in the early phase ofMCI [1,2].
Clinically,MCI is defined based on the detection of cogni-
tive decline greater than that expected at any given age and
less than that observed in dementia in the context of preserved
activities of daily living and the absence of other neurologicalreported no conflicts of interest. This study is not in-
uthor. Tel.: 161-2-6125-9032; Fax: 161-2-6125-
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).disorders. However, clinical evaluation is complicated by
heterogeneity in cognitive reserve and diversity in daily func-
tion. Considering that each cognitive measure is designed to
target a particular brain function, selecting which cognitive
measures are appropriate to assess functional decline in the
MCI trajectory is a matter of concern not only for diagnostic
purposes but also in the evaluation of clinical trials [3].
Besides higher uncertainty in characterizing MCI based on
functional impairment [4], cognitive evaluation is not
currently informative enough for demonstrating patterns of
deterioration that will accurately discriminate those who
will remain stable from thosewhowill convert to AD or other
dementias. Therefore, without a better understanding of the
neurologic basis of the disorder, as well as the identification
of structural biomarkers, reliable detection of MCI and esti-
mation of future risk of dementia remain elusive.
Assuming that impairment in cognitive function is the
result of neurodegeneration, monitoring structural brain
changes may be beneficial in understanding the pathophysi-
ology of MCI. Recent development in neuroimagingimer’s Association. This is an open access article under the CC BY-NC-ND
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structural biomarkers in living subjects. In the past two de-
cades, the use of magnetic resonance imaging (MRI) to
assess cerebral structure has becomewidespread. Most early
studies have used a cross-sectional design and have sug-
gested that, although the presence of structural differences
in any particular brain area is not specific to MCI or AD
(i.e. it can also be observed in “normal” aging), the pattern
of regional atrophy rates and the topological progression
of atrophy are quite characteristic, particularly in AD [5].
Moreover, these studies also revealed that regional atrophy
rates are different in MCI and AD [6]. Consequently, identi-
fication of regionally specific atrophy rates in MCI may be
beneficial for detecting the early stage of AD development,
as well as evaluating the magnitude of expected structural
changes in clinical trials.
Available longitudinal studies have identified a subset of
brain areas that may be involved in MCI pathology. An
important next step is to combine, contrast, and integrate
the findings from different studies to produce normative in-
formation on regional atrophy rates, and to identify the most
sensitive anatomic biomarkers characteristic for MCI. As far
as we are aware, no study has systematically summarized
these findings to date. Therefore, the aim of this study was
to systematically review the literature concerning MCI-
related structural brain changes.2. Methodology
This systematic review was conducted based on an estab-
lished methodology [7], using prespecified search terms and
inclusion and exclusion criteria, and was performed accord-
ing to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines [8].
To retrieve all references relating to longitudinal brain
structural changes in MCI published in the MEDLINE data-
base, a literature search was conducted through the PubMed
portal in two stages, (1) at the beginning of the study (2) and
at the end of February 2015 to update pooled data with the
most recent published studies. The following search string
was used for both searches; (Brain or Cerebral or Cortical)
And (Mild Cognitive Impairment Or MCI Or Cognitive dis-
order Or Neurocognitive disorder Or Cognitive decline Or
Cognition) And (Structur* Or Volum* Or Thickness Or
MRI Or Neuroimaging) And (Atrophy Or Change Or Longi-
tudinal Or shrinkage). Both literal and Medical Subject
Heading searches were performed. Searches were limited
to studies published in English and focusing on human sub-
jects.2.1. Selection criteria and selection process
To be selected, studies were required to use a longitudinal
methodology with two or more structural MRI scans con-
ducted over a follow-up of 12 months or more. As MCI sta-
tus defined the group being compared with healthy controls(HC), cognitive status of HC and MCI was required to be
stable between all time points. Studies were required to
use Peterson or Winblad criteria for MCI diagnosis. Cross-
sectional, experimental, and review articles were excluded.
Studies were also excluded if they had a combined total of
less than 30 HC and MCI participants. All retrieved articles
were first screened by title and abstract and irrelevant studies
were excluded. The full text of all remaining articles was
double screened by two reviewers (H.T.-J. and M.E.S.)
against selection criteria.2.2. Data extraction and structural measures
Two reviewers (H.T.-J. and M.E.S.) extracted data from
all included articles and any disagreement was resolved by
consensus. Data extracted consisted of (1) study design
including sample source, number of participants in each
group, type of structural measurement, and follow-up
period; (2) participants’ demographics including age, gender
ratio, APOE ε4 ratio, years of education, dropout rate, MCI
subtype for MCI groups, subjective memory complaint for
HC, and handedness; (3) measurement details including
number of scans, scan intervals, follow-up period, MRI pa-
rameters, segmentation method, and method of analysis;
and (4) study results including areas of interest (left and
right) and effect sizes (left, right, and total).
All structural measures were evaluated, and studies were
categorized according to the following structural measure-
ments; voxel-based morphometry (VBM), volumetry,
tensor-based morphometry (TBM), cortical thickness, sulcal
morphometry, diffusion tensor imaging (DTI), white matter
hyperintensities (WMH), susceptibility weighted imaging
(SWI), and other structural measures.
Studies meeting the selection criteria were assessed for
quality using the Newcastle-Ottawa scale [9]. The
Newcastle-Ottawa scale is an instrument for assessing the
quality of studies included in a systematic review. Each
study was evaluated on eight items classified into three cat-
egories including the selection of the study groups, the
comparability of the groups, and the ascertainment of
outcome of interest. Each quality item was awarded by a
star (except two for comparability) and for each study up
to nine stars in total.2.3. Multiple reports
In the case of multiple reports for the same cohort, or any
overlap of participants, an annual change rate estimate from
only one publication was used in any single analysis. The
most appropriate reports were selected based on recency,
availability of effect size and moderators, sample size, and
methodology. Studies that reported effect sizes (or provided
them after contact) were the first priority and from those the
most recent study with the largest sample size was selected.
If there was more than one study similar in sample size and
recency, the one with the highest quality rating was selected.
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different brain areas, estimates from the same cohort but
from different studies might be used in different analyses.2.4. Statistical analysis
The R statistical software (version 3.1.1) was used for the
statistical analysis, and the metafor package (version 1.9-4)
was used for meta-analysis. The annual percentage mean at-
rophy rate was considered as the effect size, and calculation
of required standard error (SE) for meta-analysis was based
on the standard deviation and number of participants in each
group for each individual study. Availability of mean annual
atrophy rate (%/year), either reported or computed based on
other reported results, was the essential requirement for the
meta-analysis. Where insufficient data were available for in-
clusion in the meta-analysis, authors were contacted directly
to seek additional information.
2.4.1. Meta-analysis
It was assumed that the heterogeneity in the atrophy rates
across reviewed studies was the impact of the between-study
and within-study heterogeneities, and the random effects
for between- and within-studies were normally distributed.
A random-effects model using the restricted maximum
likelihood estimator was applied for all analyses. Random-
effects model was chosen based on the assumption that cere-
bral atrophy rates (effect size) are not similar in population
with different characteristics and there is no single effect
size representative of all population but an array of effect
sizes. Therefore, each included study was assumed to repre-
sent a random sample of a particular effect size and a
random-effects model estimates a mean of the distribution
of these effect sizes [10]. Separate meta-analyses were per-
formed for healthy and MCI atrophy rates and also for the
mean difference in atrophy rate between MCI and healthy
controls (MCI-HC) across each cerebral region.
Heterogeneity across studies was assessed with the Q and
I2 statistics. P value,.01 considered as significant heteroge-
neity in the Q test and in the I2 statistic values of 25%, 50%,
and 75% were suggestive of low, moderate, and high hetero-
geneity, respectively. Heterogeneity in the atrophy rates was
also assumed to be in part the result of disparities in age, sex
ratio, APOE ε4 ratio, and education levels in the studies’ par-
ticipants as well as scan intervals and different segmentation
approaches. Therefore, these variables were investigated as
possible moderators for subgroup and meta-regression ana-
lyses. Subgroup analyses were conducted to investigate the
impact of manual versus automated segmentations. Meta-
regression analyses using a mixed-effect model were con-
ducted to determine the influence of moderators.
To identify studies contributing excessively to heteroge-
neity, sensitivity analyses were conducted using the
leave-one-out method. Visual evaluation of asymmetry of
the funnel plots was used to assess the bias in the
meta-analyses results toward publication of studies withsignificant outcomes. The trim-and-fill method was used to
estimate the number of missing studies (representative of un-
reported effect sizes) in the meta-analysis to estimate
adjusted effect sizes [11].3. Results
3.1. Literature search and studies included in the review
The search strategy identified 5220 unique citations. Af-
ter exclusion of irrelevant studies based on title and ab-
stracts, 219 publications remained for full-text assessment.
A further 151 studies did not meet the inclusion criteria
and were excluded leaving 68 studies for further analysis
(Fig. 1).
Of the studies included, 45 assessed brain structure with
volumetry, nine with cortical thickness, and 18 with a wide
variety of structural measurements including sulcal
morphometry, VBM, TBM, DTI, WMH, SWI, and quantita-
tive scaling methods such as the medial temporal atrophy
scale (MTAS) [12] and the brain atrophy and legion index
(BALI) [13] (Table 1).3.2. Study quality
All studies except one, which was rated 6 [14], were rated
as high quality (eight or nine stars) based on the Newcastle-
Ottawa scale (Table 1). Fifty-four of 68 studies fulfilled the
maximum of nine stars, two studies were rated as not repre-
sentative of the population due to a higher rate of medical
diseases in the participants, and one study did not describe
the derivation of the HC. Twelve studies only controlled
for age to establish comparability between controls and
MCI participants.3.3. Multiple reports
A number of multiple reports were identified. Forty-six
studies reported on participants taking part in the Alz-
heimer’s Disease Neuroimaging Initiative (ADNI; to date
up to 229 HC and 395 MCI), four studies used Mayo AD
research center and AD patient registry data (up to 91 HC
and 72 MCI), and one study used a mixture of ADNI and
Mayo data. There was also an overlap of participants in
two studies reported by Henneman et al. [15,16]. A total
of 15 publications reported on separate independent
cohorts including in total 629 HC and 571 MCI
participants from 10 countries across four continents (eight
in Europe, five in North America, one in Asia, and one in
Australia).3.4. Compatible studies for meta-analysis
A sufficient number of compatible studies was only avail-
able for meta-analysis of volumetric measurements. Quanti-
tative report of structural measures in VBM and TBM
studies were not comparable. Brain areas investigated by
Fig. 1. Screening and selection process for studies included in the systematic review and the meta-analyses.
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compatible. There was only one study in each given category
of sulcal morphometry, WMH, and SWI. Finally, studies us-
ing MTAS and BALI scales were all based on the same
cohort except for one study (Table 1). Therefore, of the 68
studies that met the selection criteria, 24 studies could not
be included in the meta-analyses, leaving 44 volumetric
studies for inclusion. Because too few sporadic reports of lat-
erality were available, this factor could not be investigated.
There was also no report of handedness.
Volumetric studies evaluated a wide variety of brain re-
gions including the whole brain, hippocampus, entorhinal
cortex, ventricles, parahippocampal gyrus, amygdala, fusi-
form gyrus, superior temporal, medial lateral and inferiortemporal lobes, medial and lateral orbitofrontal cortex, supe-
rior frontal cortex, cingulate cortex, and parietal and occip-
ital lobes. Besides the first four measures, other brain areas
were investigated sporadically. Three of 44 studies evaluated
brain areas incompatible with other studies and were not
considered for meta-analysis. Forty-one studies were identi-
fied as potentially compatible and were included in meta-
analyses. These studies evaluated annual atrophy rate of
the whole brain (n 5 10), the hippocampus (n 5 33), and
the entorhinal cortex (n 5 10), as well as annual expansion
rate of the ventricles (n 5 14).
Of 41 studies, 29 were excluded because of overlap in
participants and one because of missing data which could
not be obtained from authors (Table 1). Although three
Table 1
Studies included in the review
# Study Address Measurement Cohort
Newcastle-Ottawa quality assessment scaley
Compatible for meta-analysisSelection Comparability Outcome
Q-1 Q-2 Q-3 Q-4 Q-5 Q-6 Q-7 Q-8 Yes/no
In
meta-analysis Details
1 Madsen et al. Neurobiology of aging
36(2015)532–541
Volumetry ADNI * * * * ** * * * Yes No Ventricle meta-analysis
due to overlap of
participants
2 Lorenzi et al. Neurobiology of Aging
36(2015)542–552
SVF ADNI * * * * ** * * * No No No quantitative structural
measure
3 Toledo et al. Acta Neuropathol
127(2014)621–632
??? ADNI * * * * ** — * * No No Incomplete report of
structural data
4 Teiple et al. Neurobiology of aging
35(2014)482–491
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
5 Mulder et al. Neurology 92(2014)
169–181
Volumetry ADNI * * * * * * * * Yes No Hip meta-analysis due to
overlap of participants
6 Marshal et al. Journal of Alzheimer’s
disease 41(2014)
719–728
Cortical thickness ADNI * * * * ** * * * No No Incompatible brain area
with other studies
7 Manning et al. PLOS ONE May (2014)
Vol 9/issue5e97608
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
8 Lilemark et al. BMC Medical imaging
(2014)14–21
Volumetry ADNI * * * * ** * * * Yes No WB and Hip
meta-analyses due to
overlap of participants
9 Kljajevic et al. Neurobiology of Aging
35(2014)1973–1981
Volumetry, cortical
thickness
ADNI * * * * ** * * * No No Incompatible brain area
with other studies
10 Insel et al. Alzheimer’s & Dementia
(2014)1–9
Volumetry ADNI * * * * ** * * * Yes No Hip and ERC
meta-analyses due to
overlap of participants
11 Guo et al. Journal of Alzheimer’s
Disease 42(2014)
691–703
BALI ADNI * * * * ** * * * No No Incompatible with
independent study
12 Aguilar et al. Frontiers in Aging
Neuroscience July
2014/Vol6/Article 145
Volumetry, cortical
thickness
AddNeuroMed * * * * ** * * * Yes No Missing and mismatch
data
13 Nowrangi et al. Alzheimer’s & Dementia
9(2013)519–528
DTI Community-dwelling
volunteers
* * * * * * * * No No Incompatible brain area
with other studies
14 Guo et al Alzheimer’s & Dementia
9(2013)580–586
Volumetry ADNI * * * * ** * * * Yes No WB meta-analysis due to
overlap of participants
15 Franko et al. PLOS ONE Aug. (2014)
Vol 8/issue 8/e71354
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
16 Adaszewski et al. Neurobiology of Aging
34(2013)2815–2826
VBM, SVM ADNI * * * * * * * * No No No quantitative structural
measures
17 Villemagne et al. Lansent Neural 12(2013)
357–367
Volumetry AIBL * * * * ** * * * Yes Yes Hip meta-analysis
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Table 1
Studies included in the review (Continued )
# Study Address Measurement Cohort
Newcastle-Ottawa quality assessment scaley
Compatible for meta-analysisSelection Comparability Outcome
Q-1 Q-2 Q-3 Q-4 Q-5 Q-6 Q-7 Q-8 Yes/no
In
meta-analysis Details
18 Song et al. J Neurosurg Psychiatry
84(2013)71–78
MTAS, BALI ADNI * * * * ** * * * No No Incompatible with
independent study
19 Selnes et al. Journal of Alzheimer’s
Disease 33(2013)
723–739
DTI Memory clinics * * * * ** * * * No No Incompatible brain area
with other studies
20 Liu et al. NeuroImage 74(2013)
337–342
Sulcal morphology,
cortical thickness
MAS * * * * * * * * No No Incompatible brain area
with other studies
21 Gutman et al. NeuroImage 70(2013)
386–401
Volumetry ADNI * * * * * * * * Yes No Ventricles meta-analysis
due to overlap of
participants
22 Zhang et al. Dement Geriat Cogn
Disord 33(2012)
318–326
MTAS, BALI ADNI * * * * ** * * * No No Incompatible with
independent study
23 Yao et al. PLOS ONE (2012)
Vol 7/Issue 11/e48973
Cortical thickness ADNI * * * * ** * * * No No Incompatible brain area
with other studies
24 Schuff et al. Neurobiology of Aging
33(2012)845–855
Volumetry ADNI * * * * * * * * Yes Yes ERC meta-analysis
25 McDonald et al. Neurobiology of Aging
33(2012)242–253
Volumetry ADNI * * * * ** * * * No No Due to mismatch of brain
areas
26 Li et al. Neurobiology of Aging
33(2012) 427 e15–30
Cortical thickness ADNI * * * * ** * * * No No Incompatible brain area
with other studies
27 Leung et al. NeuroImage 59(2012)
3995–4005
Volumetry ADNI * * * * * * * * No No Mismatch data
28 Andrawis et al. Neurobiology of Aging
33(2012)856–866
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
29 Zhang et al. Journal of Alzheimer’s
Disease 26(2011)
359–367
BALI ADNI * * * * ** * * * No No Incompatible with
independent study
30 Tosun et al. Journal of Alzheimer’s
Disease 26(2011)
77–90
Cortical thickness ADNI * * * * ** * * * No No Incompatible brain area
with other studies
31 Skup et al. NeuroImage 56(2011)
890–906
Volumetry ADNI * * * * ** * * * Yes No Hip and ERC meta-
analyses due to overlap
of participants
32 Mouiha et al. Neuroscience Letters
495(2011)6–10
Volumetry ADNI * * * * * * * * Yes No Hip meta-analysis due to
overlap of participants
33 Lo et al. Arch Neurol. Oct. (2011)
Vol 68, No. 10
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
34 Desikan et al. Ann Neurol 70(2011)
657–661
Volumetry ADNI * * * * ** * * * Yes No ERC meta-analysis due to
overlap of participants
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Table 1
Studies included in the review (Continued )
# Study Address Measurement Cohort
Newcastle-Ottawa quality assessment scaley
Compatible for meta-analysisSelection Comparability Outcome
Q-1 Q-2 Q-3 Q-4 Q-5 Q-6 Q-7 Q-8 Yes/no
In
meta-analysis Details
35 Chiang et al. Alzheimer’s & Dementia
7(2011)514–520
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
36 Villain et al. Brain 133(2010)
3301–3314
VBM Memory Clinic * * * * ** * * * No No No quantitative structural
measure
37 Vemuri et al. Neurology 75(2010)
143–151
Volumetry ADNI * * * * ** * * * Yes No WB meta-analysis due to
overlap of participants
38 Tosun et al. Neurobiology of Aging
31(2010)1340–1354
Volumetry, cortical
thickness
ADNI * * * * ** * * * Yes No Ventricle, hip and ERC
meta-analyses due to
overlap of participants
39 Stoub et al. Neurobiology of Aging
31(2010)1089–1098
Volumetry RADC & ROS
and MAP
* * * * ** * * * Yes No Hip and ERC meta-
analyses due to overlap
of participants
40 Schott et al. Neurobiology of Aging
31(2010)1452–1462
Volumetry ADNI * * * * ** * * * Yes Yes WB and hip meta-
analyses
41 Prestia et al. Journal of Alzheimer’s
Disease 22(2010)
1339–1349
VBM TOMC * * * * ** * * * No No No quantitative structural
measure
42 Leung et al. NeuroImage 51(2010)
1345–1359
Volumetry ADNI * * * * * * * * Yes No Hip meta-analysis due to
overlap of participants
43 Hua et al. Neurobiology of Aging
31(2010)1463–1480
TBM ADNI * * * * ** * * * No No Incompatible brain area
with other studies
44 Ho et al. Human Brain Mapping
31(2010)499–514
TBM ADNI * * * * * * * * No No Incompatible brain area
with other studies
45 Evans et al. Eur Radiol. 20(2010)
674–682
Volumetry ADNI * * * * ** * * * Yes No WB and ventricle meta-
analyses due to overlap
of participants
46 Desikan et al. PLOS ONE (2010) Vol
5/Issue 9/e12853
Volumetry, Cortical
Thickness
ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
47 Carmichael et al. Arch Neurol. 67(2010)
1370–1378
WMH ADNI * * * * ** * * * No No Incompatible with
independent study
48 Beckett et al. Alzheimer’s & Dementia
6(2010)257–264
Volumetry ADNI * * * * ** * * * Yes No Hip and ventricle meta-
analyses due to overlap
of participants
49 Ayaz et al. Journal of Magnetic
Resonance Imaging
31(2010)142–148
SWI ??? — — * * * * * * No No Incompatible with
independent study
50 Archer et al. Int J Geriatr Psychiatry
25(2010)1119–1126
Volumetry Hospital
& memory clinic
* * * * ** * * * Yes Yes WB and hip meta-
analyses
51 Apostolova et al. NeuroImage 51(2010)
488–499
Volumetry ADNI * * * * ** * * * No No Hip meta-analysis due to
overlap of participants
(Continued )
H
.
Ta
b
a
ta
b
a
ei-Ja
fa
ri
et
a
l.
/
A
lzh
eim
er’s
&
D
em
en
tia
:
D
ia
g
n
o
sis,
A
ssessm
en
t
&
D
isea
se
M
o
n
ito
rin
g
1
(2
0
1
5
)
4
8
7
-5
0
4
4
9
3
Table 1
Studies included in the review (Continued )
# Study Address Measurement Cohort
Newcastle-Ottawa quality assessment scaley
Compatible for meta-analysisSelection Comparability Outcome
Q-1 Q-2 Q-3 Q-4 Q-5 Q-6 Q-7 Q-8 Yes/no
In
meta-analysis Details
52 Wang et al. Psychiatric research
neuroimaging
171(2009)221–231
Volumetry Neurological clinic * * * * ** * * * Yes Yes Hip meta-analysis
53 Sluimer et al. Eur Radio. 19(2009)
2826–2833
Volumetry Memory clinic * * * * ** * * * No No Incompatible brain area
with other studies
54 Schuff et al. Brain 132(2009)
1067–1077
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
55 Morra et al. NeuroImage 45(2009)
s3–15
Volumetry ADNI * * * * ** * * * Yes No Hip meta-analysis due to
overlap of participants
56 Leow et al. NeuroImage 45(2009)
645–655
TBM ADNI * * * * ** * * * No No Incompatible brain area
with other studies
57 Jack Jr. et al. Brain 132(2009)
1355–1365
Volumetry Mayo, ADNI * * * * ** * * * Yes No Ventricle meta-analysis
due to overlap of
participants
58 Hua et al. NeuroImage 48(2009)
668–681
TBM ADNI * * * * * * * * No No Incompatible brain area
with other studies
59 Holland et al. PNAS (2009) Vol 106/No.
49/20,954–20,959
Volumetry ADNI * * * * ** * * * Yes No WB, ventricle, hip and
ERC meta-analyses
due to overlap of
participants
60 Henneman et al. Neurology 73(2009)
935–940
Volumetry Memory clinic * * * * ** * * * Yes Yes Hip meta-analysis
61 Henneman et al. Neurology 72(2009)
999–1007
Volumetry Memory clinic * * * * ** * * * Yes Yes WB meta-analysis
62 Brys et al. Journal of Alzheimer’s
Disease 16(2009)
351–362
VBM, MTL-rBS AD research center * * * * ** * * * No No Incompatible with
independent study
63 Jack Jr. et al. Neurology 70(2008)
1740–1752
Volumetry Mayo * * * * ** * * * Yes No WB and ventricle meta-
analyses due to overlap
of participants
64 Eckerstrom et al. Journal of the
Neurological sciences
272(2008)48–59
Volumetry Goteborg MCI study — * * * ** * * * Yes Yes Hip meta-analysis
65 Desikan et al. Neurology 71(2008)
819–825
Volumetry Community-dwelling
volunteers
* * * * ** * * * Yes Yes Hip and ERC meta-
analyses
66 Jack Jr. et al. Neurology 65(2005)
1227–1231
Volumetry Mayo * * * * ** * * * Yes Yes WB, hip and ERC meta-
analyses
67 Jack Jr. et al. Neurology 62(2004)
591–600
Volumetry Mayo * * * * ** * * * Yes No WB, ventricle, hip and
ERC meta-analyses
due to overlap of
participants
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H. Tabatabaei-Jafari et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 487-504 495studies were available for ventricle expansion analysis, re-
ported expansion rates did not use the same units (mL/year
vs. %/year) and requests for more information from authors
was not successful. Therefore, meta-analysis could not be
conducted for this region. Final numbers of studies included
in the meta-analyses were four for whole brain, eight for hip-
pocampal, and three for entorhinal cortex atrophy (Table 2).
3.4.1. Whole brain atrophy
Four studies [16–19], which were included for whole
brain analysis (Fig. 2), surveyed 351 control and 466 MCI
participants over an average follow-up of 1.30 years (range
1.00–1.80). Estimated mean atrophy rates were 1.02%/year
(SE 5 0.13) for MCI and 0.57%/year (SE 5 0.03) for
controls. Thus, the additional annual total brain atrophy
attributable to MCI above the effect of “normal” aging was
0.46%/year (SE5 0.10). There was no significant heteroge-
neity (based on the Q test) for whole brain atrophy rates in
HC and MCI after removing the effect attributable to normal
aging (MCI-HC). The proportion of real observed variance
(not related to random error) between studies (I2) was mod-
erate in MCI-HC and high in MCI (Table 3).
3.4.2. Hippocampal atrophy
Of eight studies [15,17–23], which were included for
hippocampal meta-analysis, one study [22] reported an in-
crease in hippocampal volume in MCI and a decrease in vol-
ume in HC as well as standard deviations larger than twice
the mean atrophy rates. These characteristics were inter-
preted as being potentially methodologically problematic
and after further investigation, the study was excluded
from the meta-analysis because it was remarkably different
in quality and design compared with other studies in the
group, including gender proportion misbalance and high
level of medical illness in the participants.
The remaining seven studies estimated hippocampal atro-
phy rates for 487 HC and 540 MCI participants with an
average follow up of 1.97 years (range 1–3.8) (Fig. 2). The
estimated mean atrophy rates were 2.53%/year
(SE 5 0.33) for MCI, 1.12%/year (SE 5 0.16) for controls,
and 1.35%/year (SE5 0.19) for MCI after removing the ef-
fect attributable to normal aging. Significant heterogeneity
was found for hippocampal atrophy rates in MCI and
MCI-HC but not in HC. The proportion of real observed
variance (not related to random error) between studies (I2)
was moderate to high in all groups (Table 3).
3.4.3. Entorhinal cortex annual atrophy
Three studies [19,23,24], which were included for
entorhinal cortex meta-analysis (Fig. 2), surveyed 257 con-
trols and 258 MCI participants, followed up for 2.28 years
(range 1.25–3.00). Estimated mean atrophy rates were
3.75%/year (SE 5 1.60) for MCI and 2.41%/year
(SE 5 1.30) for HC. After removing the effect attributable
to normal aging, the mean atrophy rate exclusively associ-
ated with MCI was 1.13%/year (SE 5 0.33). Significant
Table 2
Studies included in meta-analyses
First author, year
Measurement
Recruit
Participants Age Female % APOE ε4 % Change rate
WB Hip ERC Vent* HC MCI HC MCI HC MCI HC MCI HC MCI
Villemagne, 2013 ✔ AIBL 112 32 71.2 (7.2) 74.2 (6.6) 48.21 43.75 46 65 20.911 (1.15) %/y 22.15 (1.33) %/y
Schuff, 2012 ✔ ADNI 147 164 76 (5) 75 (7) 49.66 37.8 22 45 21.6 (0.4) %/y 22.4 (0.4)
Schott, 2010 ✔ ADNI 199 334 76 (5.1) 74.9 (7.2) 46.73 36.53 28.64 53.3 20.592 (0.581) %/y 21.08 (0.84) %/y
✔ 21.01 (1.72) %/y 22.63 (2.35) %/y
✔ 21.43 (1.63) mL/y 2285 (2.75) mL/y
Archer, 2010 ✔ Clinic 27 16 62.3 (8.3) 67.1 (6.9) 51.85 31.25 18.5 75 20.47 (0.67) %/y 21 (0.81) %/y
✔ 20.78 (0.91) %/y 22.8 (1.68) %/y
✔ 21.14 (1.73) mL/y 23.62 (2.33) mL/y
Wang, 2009 ✔ Clinic 20 39 75.1 (3.7) 75.6 (3.6) 45 20.51 20 26.5 21 (0.7) %/y 22.1 (1.5) %/y
Henneman, 2009a ✔ Clinic 19 25 66 (9) 71 (6) 42.11 56 47 71 22 (1.5) %/y 23.7 (1.2) %/y
Henneman, 2009b ✔ Clinic 34 44 67 (9) 71 (6) 47.06 47.72 _ _ 20.6 (0.6) %/y 21.3 (0.9) %/y
Eckerstromy, 2008 ✔ GMS 19 15 ? ? ? ? ? ? 20.168 (0.464) mL/y 10.082 (0.329) mL/y
Desikan, 2008 ✔ Media 19 22 69.7 (3.7) 70.1 (4.4) 63.16 59.1 31.6 31.8 20.71 (0.88) %/y 21.13 (1.01) %/y
✔ 20.68 (1.4) %/y 21.92 (2.12) %/y
Jack Jr, 2005 ✔ MAYO 91 72 80.5 (?) 78.7 (?) 60.44 43.06 _ _ 20.5 (0.7) %/y 20.7 (1) %/y
✔ 21.7 (1.4) %/y 23.3 (2.7) %/y
✔ 25 (3.6) %/y 27 (4.3) %/y
✔ 22.4 (2) %/y 23.3 (2.3) %/y
Abbreviations:WB, whole brain; hi, hippocampus; ERC, entorhinal cortex; vent, ventricles; HC, healthy controls; MCI, mild cognitive impairment; AIBL, Australian Imaging, Biomarker, and Lifestyle; ADNI,
Alzheimer’s Disease Neuroimaging Initiative; GMS, Goteborg MCI study; MAYO, Mayo AD research center and AD patient registry.
Measures provided as mean (standard deviation).
*Ventricular studies were not matched in atrophy rate unit and excluded from the meta-analyses.
yThis study was an outlier and excluded from final hippocampal meta-analysis.
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Fig. 2. Forest plots of atrophy rates for (A) whole brain, (B) hippocampus, and (C) entorhinal cortex in healthy controls, MCI, and the difference in atrophy rate
between MCI and healthy controls (MCI-HC). Studies are ordered by year of publication. Abbreviations: MCI, mild cognitive impairment; CI, confidence in-
terval.
H. Tabatabaei-Jafari et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 487-504 497heterogeneity was identified in entorhinal cortex atrophy
rates in MCI and HC but not MCI-HC. The proportion of
real observed variance (not related to random error) between
studies (I2) was moderate to high in all groups (Table 3).
3.4.4. Sensitivity analyses
The influence of single studies was investigated with
leave-one-out analyses. Globally, the analysis revealed no
particularly influential study and showed consistency in re-
ported estimates.
3.4.5. Publication bias
Some evidence of publication bias was detected based on
the funnel plot asymmetry diagnostic and the trim-and-fill
test. The funnel plots revealed some degree of asymmetry
for all three groups of analyses (the whole brain, hippocam-
pus, and entorhinal), and the trim-and-fill method identified
one or two missing studies in each analysis group. One
missing study was identified in the whole brain and hippo-
campal analyses and two studies in entorhinal analysis, rep-
resenting 20%, 12.5%, and 40% of included studies,
respectively. Although asymmetry and presence of missingstudies suggest some publication bias toward studies report-
ing higher atrophy rates, the differences between actual and
reported atrophy rates were generally small, particularly for
the hippocampus (Fig. 3).
3.4.6. Subgroup and meta-regression analyses
The influence of segmentation methods (automatic vs.
manual), MCI subtype (amnestic MCI vs. MCI), female pro-
portion, APOE ε4 genotype, and sample mean age on pooled
estimates was investigated by subgroup meta-analyses and
meta-regression on hippocampal volumetry only, as too
few studies were available for other regions of interest
(Table 3). Subgroup analyses showed that the estimated
mean hippocampal atrophy rates in studies [15,19,21]
using manual segmentation were significantly higher than
studies [17,18,20,23] using automatic segmentation (Fig. 2
and Table 3) by 68% in HC, 40% in MCI, and 7% in MCI-
HC. Additionally, subgroup analysis of MCI subtypes
(amnestic MCI vs. MCI) showed significantly higher hippo-
campal atrophy rate in amnestic MCI [19,21] compared with
MCI (all subtypes) [15,17,18,20,23] (2.68%/year
[SE 5 0.66] vs. 2.47%/year [SE 5 0.42]) in MCI
Table 3
Random-effect models of whole brain, hippocampus, and entorhinal cortex atrophy rates in healthy controls, MCI, and in MCI after removing the effect
attributed to normal aging and subgroup and meta-regression analyses of hippocampal atrophy rate in MCI after removing the effect attributed to normal aging
Random-effects model
Brain areas K Age
Estimate
%/year SE 95% CI Z-value P value T2 T I2 % H2
Test for heterogeneity
df Q P value
Whole brain (K 5 4)
HC 351 71.45 20.5665 0.0328 20.6308 20.5023 217.2757 ,.0001 0 0 0 1.0 3 1.8707 .5997
MCI 466 72.92 21.0203 0.1263 21.2679 20.7727 28.0772 ,.0001 0.0477 0.2185 79.98 4.99 3 12.6691 .0053
MCI-HC — — 20.4634 0.0987 20.6569 20.2699 24.6944 ,.0001 0.0194 0.1393 51.86 2.08 3 5.7540 .1242
Entorhinal cortex (K 5 3)
HC 257 75.40 22.4146 1.3036 24.9696 0.1505 21.8522 .0640 5.0168 2.2398 98.81 83.72 2 89.1356 ,.0001
MCI 258 74.60 23.754 1.6065 26.9028 20.6052 22.3367 .0195 7.5905 2.7551 98.51 67.29 2 83.2905 ,.0001
MCI-HC — — 21.1301 0.3373 21.7911 20.4691 23.3509 .0008 0.1936 0.4400 52.49 2.10 2 4.1965 .1227
Hippocampus (K 5 7)
HC 487 71.54 21.1197 0.1622 21.4376 20.8019 26.9048 ,.0001 0.1513 0.3890 86.22 7.26 6 34.2283 ,.0001
MCI 540 73.09 22.5303 0.3261 23.1694 21.8912 27.7598 ,.0001 0.6741 0.8211 92.87 14.02 6 78.1854 ,.0001
MCI-HC — — 21.3450 0.1906 21.7186 20.9715 27.0571 ,.0001 0.1556 0.3945 64.69 2.83 6 16.5628 .0110
Subgroup and meta-regression analyses
Hippocampus;
MCI-HC K Age Coef SE 95% CI Z-value P value T2 T I2 % H2 R2
Residual hetrogeneity
df QE P value
Model 1
Automatic
segmentation
4 71.57 21.2900 0.2682 21.8156 20.7644 24.8106 ,.0001 0.2019 0.4494 69.90 3.32 — 5 16.5244 .0055
Manual
segmentation
3 75.1 21.4383 0.3289 22.0829 20.7936 24.3730 ,.0001
Model 2
aMCI 2 77.15 21.3337 0.3939 22.1057 20.5618 23.3863 .0007 0.2091 0.4572 70.73 3.42 — 5 16.4832 .0056
MCI 5 71.46 21.3562 0.2488 21.8438 20.8686 25.4510 ,.0001
Model 3
Intercept — — 20.9973 5.0703 210.9349 8.9403 20.1967 .8441 0.0384 0.1960 36.24 1.57 79.71 2 2.9841 .2249
Age — — 0.0006 0.0640 20.1249 0.1261 0.0093 .9926
Female rate — — 0.0209 0.0132 20.0050 0.0467 1.5821 .1136
APOE ε4 rate — — 20.0233 0.0088 20.0406 20.0061 22.6477 .0081
Abbreviations: SE, standard error; CI, confidence interval; T, standard deviation of true effects; df, degrees of freedom; HC, healthy control; MCI, mild cogni-
tive impairment; Coef, coefficient; aMCI 5 amnestic MCI; r2, proportion of observed dispersion accounted for by the model; H2, total variability/sampling
variability; R2, heterogeneity accounted for the moderator(s); Q, heterogeneity; QE, residual heterogeneity.
H. Tabatabaei-Jafari et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 487-504498participants. After removing the effect attributable to normal
aging, the hippocampal atrophy rate was significantly higher
in analyses including all generic/unspecified MCI (1.35%/
year, SE 5 0.25) compared with those including amnestic
MCI only (1.33%/year, SE 5 0.39). However, the atrophy
rate difference was relatively small especially in MCI-HC
analyses, and also numbers of studies in each subgroup
were limited. In addition, (as it is notified in the discussion)
studies, which were not specific in detecting MCI subtype,
generally used cognitive measures that commonly used for
detecting amnestic MCI in other studies.
The influence of age, female gender, and APOE ε4 rate on
hippocampal atrophy was separately investigated in HC,
MCI, and MCI-HC. Except for APOE ε4, which signifi-
cantly predicted the unexplained variance (55.38%) in
annual atrophy rate, age and female gender did not
contribute substantially to the heterogeneity detected be-
tween studies. A mixed-effects model using age, female
gender, and APOE ε4 rate as moderators accounted for79.7% of heterogeneity in hippocampal atrophy rate in
MCI-HC; however, only APOE ε4 rate was a significant
moderator of atrophy rate (Table 3).3.5. Incompatible studies3.5.1. Ventricular expansion
Although it was not possible to produce a pooled estimate
of ventricular expansion rate because of insufficient reports
of separate cohorts, the remaining studies reported very
similar estimates [17,18,25] of, on average, twofold
(3.30%/year vs. 2.40%/year in one report and 2.85 mL/
year vs. 1.43 mL/year and 3.62 mL/year vs. 1.14 mL/year
in two other reports) increase in expansion rate in MCI
compared with HC. When considering that whole brain
volume is about 1200–1500 mL, reported ventricular
expansion rate is approximately 0.1%/year of the whole
Fig. 3. Funnel plots of (A) whole brain, (B) hippocampus, and (C) entorhinal cortex using random-effects model (left column) and trim-and-fill method
(right column). Filled circles represent included studies in the meta-analyses, and open circles represent possible missing studies.
H. Tabatabaei-Jafari et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 487-504 499brain volume in HC and 0.2%/year of the whole brain
volume in MCI.
3.5.2. Gray matter atrophy
Besides the hippocampus and entorhinal cortex, which
were the focus of most volumetric studies, there were also
sporadic reports of volume loss for other parts of the brain
including the parahippocampus, amygdala, and fusiform gy-
rus [23], lateral temporal lobe [26], cingulate [23,26], insula
[6], parietal lobe [6,23,26], frontal and occipital lobes
[6,26]. Atrophy rates in these regions were less than the
average hippocampal atrophy rate and also differed based
on the clinical outcome. Volume loss in the temporal and
parietal lobes was higher for MCI subjects who had
converted to AD within 4–5 years compared with stable
MCI (lowest Cohen d for the inferior parietal lobe 5 0.53
and largest for the hippocampus 5 1.39) [23]. However,
in clinically diagnosed AD, the atrophy rate in the medial
temporal lobe was less than in MCI, whereas volume loss
in frontal, parietal, and occipital regions was greater in
MCI than AD [6].3.5.3. Cortical thickness and sulcal morphometry
Cortical thickness was the second most commonly re-
ported structural measure. Reports covered almost all parts
of the brain but without quantitative estimates amenable to
meta-analysis. Overall, studies revealed that controls and
MCI participants demonstrated a similar spatial distribution
of cortical loss, specifically in the parahippocampal cortex,
middle/inferior temporal gyrus, supramarginal gyrus,
angular gyrus, and superior frontal gyrus [27]. However,
these studies suggested that atrophy rates were higher (no
report of effect size) inMCI than controls, mainly in the tem-
poral, superolateral parietal, and frontal lobes [28,29]. The
only available longitudinal sulcal morphometry study
showed an almost twofold higher rate of superior frontal
and superior temporal sulcal widening in MCI compared
with controls [30].
3.5.4. White matter
A minority of studies evaluated longitudinal changes in
white matter. Recent DTI studies demonstrated a loss of
integrity (increase in mean diffusivity) in the white matter
H. Tabatabaei-Jafari et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 487-504500fiber tracts [31] particularly in the fornix (fitted mean
changes in mean diffusivity over 12 months of 0.003 in con-
trols vs. 0.051 inMCI), inferior and anterior cingulum (fitted
mean changes in mean diffusivity over 6 months of 20.003
in controls vs. 0.013 in MCI) [32], in MCI compared with
controls. DTI studies were limited in number and restricted
to regions of interest evaluation.4. Discussion
This study aimed to systematically review the literature
on longitudinal structural brain changes specific to stable
MCI. The main findings of this review were that (1) atrophy
rates were 1.5–2.2 times larger in MCI participants than HC;
(2) atrophy rate estimates were greater when assessed with
manual than automatic segmentation; and (3) age, sex, and
APOE ε4 were the most important moderators and together
explained almost 80% of the between-study heterogeneity.4.1. Global and local atrophy
Whole brain annual atrophy rate in MCI was twice that
observed in controls. After removing the effect of normal ag-
ing, MCI-related shrinkage was estimated at 0.46%/year or
almost 5 mL per year. This finding was consistent with
studies reporting approximately 0.1%/year ventricular
expansion in MCI in addition to that observed in normal ag-
ing [17,18,25], when considering that 20%–25% of the
whole brain shrinkage is accounted for ventricular
expansion [33].
Shrinkage in the whole brain is not necessarily the result
of homogenous atrophy in all parts of the brain. Studies us-
ing measurement of cortical thickness and gray/white matter
density in different parts of the brain demonstrated that atro-
phy rates in different brain regions were different and that
some areas were more susceptible to neurodegeneration in
normal aging as well as MCI-related degeneration
[6,21,29,30]. Studies suggested that in MCI, noticeable
atrophy was restricted to the medial temporal lobe,
whereas frontal lobe and sensory motor cortices remained
less atrophic until late in AD [34,35]. Additionally,
previous evidence suggested that medial temporal lobe
atrophy was higher in MCI participants who converted to
AD compared with those with stable MCI [34,36].
It is important to consider that most reviewed studies used
general diagnostic criteria to recruit MCI participants and
did not investigate MCI subtypes. However, study design
and cognitive tests, which were used in these studies, sug-
gested that there was probably a higher prevalence of amnes-
ticMCI inMCI participants. Therefore, reported findings are
likely to be more representative of amnestic MCI than other
MCI subtypes.
The hippocampus and entorhinal cortex were two of the
most commonly investigated subregions of the medial tem-
poral lobe, and direct evaluation of the medial temporal lobe
volume change was not an issue in volumetric studies.Therefore, there is no estimation of the whole medial tempo-
ral lobe atrophy rate in the literature. However, overall atro-
phy rates in these medial temporal lobe subregions were
similar to the whole brain atrophy rate, i.e., approximately
twice in MCI compared with HC. Although, to our knowl-
edge, there is no other systematic review of brain areas atro-
phy rates in MCI, a systematic review estimating annual
hippocampal atrophy rate in healthy aging across the life
span revealed hippocampal annual atrophy rate of 1.12%/
year in healthy aging over the age of 70 years [7], which is
consistent with the present findings. The roles of the hippo-
campus and entorhinal cortex in memory function have been
known for a long time and the association between atrophy
rates in these regions and cognitive decline has been well
documented in MCI. However, the mean estimates of annual
atrophy rates in these regions do not explain a 5-mL annual
reduction in the whole brain volume. The cerebral atrophy
observed in MCI above that detected in normal aging was
1.35%/year in the hippocampus and 1.35%/year in the ento-
rhinal cortex. This indicates a total annual volume loss of
about 0.07 mL in these areas [33], which covers less than
1.5% (of 5 mL) of the whole brain annual volume loss.
This suggests that volume loss in areas well known for mem-
ory and cognition may only be the tip of the iceberg. In sum-
mary, although most available evidence has suggested that
high rates of atrophy are mostly restricted to the medial tem-
poral lobe in stable MCI, this conclusion might be due to
underinvestigation of other cerebral regions.4.2. Gray matter and white matter
Apart from medial temporal lobe atrophy, decrease in
gray matter volume was reported in the lateral temporal, pa-
rietal, and frontal lobes [37]. These findings are consistent
with reports demonstrating cortical thinning in the superolat-
eral parietal lobe and some regions of the frontal cortex [29]
as well as sulcal widening in the superior temporal and supe-
rior frontal sulci [30]. There are also sporadic reports sug-
gesting decrease in the volume of the parahippocampal
gyrus, amygdala, fusiform gyrus, superior temporal lobe
[23], lateral temporal lobe [26], inferior temporal lobe
[23], frontal lobe [6,26], cingulate [26], parietal and occipi-
tal lobes [6,26], and insula [6]. Therefore, although higher
atrophy rates have been prominently reported in the medial
temporal lobe and the atrophy rate in this region was posi-
tively associated with cognitive decline, brain atrophy is
also widely distributed to other parts of the temporal, parie-
tal, and frontal lobes. Nonetheless, in spite of the widespread
gray matter atrophy, estimated atrophy rates in these areas
alone cannot explain the whole brain atrophy rate. Indeed,
the gray matter forms less than half of the brain tissue and
atrophy rates as high as the atrophy rate in the hippocampus
are needed in all parts of the gray matter to explain the total
brain volume loss.
Therefore, atrophy of white matter is likely to signifi-
cantly contribute to whole brain atrophy, especially
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the gray matter and theoretically cell loss in gray matter
atrophy should have an impact on white matter integrity.
Loss of integrity in the white matter fiber tracts, particu-
larly in the fornix and anterior and inferior cingulum,
has been detected by DTI studies [31,32]. These studies
are limited in number and restricted in the selection of
regions of interest. A relationship between hippocampal
gray matter atrophy and subsequent disruption in the
uncinated fasciculus and the cingulum bundle has also
been reported [37].
Although too few studies investigating white matter atro-
phy were available for review and for reliable assessment of
their magnitude, they suggest that white matter is not spared
from MCI pathology. However, the rate of atrophy in white
matter and its association with gray matter and whole brain
volume loss are some important unanswered questions.
White matter forms the dominant proportion of brain struc-
ture, which reflects the importance of connection and net-
works in neural structure and consequently brain function.
Therefore, it is essential that more investigations focus on
these questions.
Furthermore, although neuroimaging studies largely
interpret their results in relation to neural tissue, the brain
also consists of connective tissue forming the brain’s struc-
tural frame, supporting neural content and providing nutri-
ents to neural tissue. This structural frame has an
important role in preserving neural integrity and brain func-
tion. Therefore, any change in brain connective tissue may
affect the structure and function of the neural system. The ef-
fect of aging on connective tissues in other parts of the body,
including the skin, has been well documented, but the
involvement of brain connective tissue in aging and age-
related disorders needs to be evaluated in more detail. In
summary, further longitudinal investigation of non–gray
matter (e.g., white matter and connective tissue) atrophy
might be informative and may help explain gaps in our un-
derstanding of pathologic processes associated with MCI
and dementia.4.3. Segmentation method
We investigated the impact of segmentation methodolo-
gies (manual vs. automated) through meta-regression
analyses and found that manual segmentation of the hippo-
campus resulted in larger atrophy rate estimates compared
with automatic segmentation using FreeSurfer. Although
previous studies suggested that automatic segmentation
with FreeSurfer resulted in a larger estimation of hippo-
campal volume in comparison with manual segmentation
of the same images [38,39], atrophy rates have been
reported to be lower in investigations using automatic
segmentation [40]. As detailed in Fig. 2, differences be-
tween manual and automatic estimations of hippocampal
atrophy are bigger in HC than MCI participants (68%
compared with 40%), and in MCI (after removing theeffect of normal aging), the difference is remarkably less
than HC (7% compared with 68%).
As suggested by Wenger et al. [39], automatic segmen-
tation may classify some nonhippocampal tissue—with
lower atrophy rate—as hippocampal tissue. This would
explain how the automatic approach could result in higher
volume estimates but lower atrophy rate. A systematic re-
view by Fraser et al. [7], estimating annual hippocampal at-
rophy rate in healthy aging across the life span, also
detected a similar difference between manual tracing and
automatic FreeSurfer segmentation and suggested that
most studies using manual tracing excluded the tail of hip-
pocampus and estimate the atrophy rate based on the atro-
phy of the head of the hippocampus. They concluded that
hippocampal atrophy in HC was mostly restricted to the
head of the hippocampus, rather than the tail; therefore,
manual approaches, which excluded the tail, were likely
to estimate a lower atrophy rate compared with automatic
FreeSurfer approaches, which included the tail. In sum-
mary, although manual tracing is traditionally considered
as the gold standard method of hippocampal volume esti-
mation, the difference between manual tracing and auto-
matic approaches appears to be largely related to the
subregions included in each method, rather than the accu-
racy of estimation.4.4. Moderators
An important question is whether study-specific factors
such as age, female gender, and APOE ε4 influenced the
reported estimates of brain atrophy in MCI. To investigate
this question, we performed a mixed-effects model anal-
ysis for hippocampal atrophy rates (the largest analysis
group). The results showed that these moderators ac-
counted for almost 80% of the observed heterogeneity be-
tween studies, with APOE ε4 showing the largest
moderating effect.
Moderating effects of age on brain atrophy have been
well documented, although the pattern of association
needs more investigation. It seems that this association
is nonlinear and that the atrophy rate in stable MCI is
larger at younger than older ages [41] although this was
not confirmed in our meta-regression, possibly be due to
a narrow age range as well as small number of studies
in the meta-regression. Indeed, research consistent with
this finding suggests that a higher whole brain atrophy
rate is present in female compared with male individuals
with MCI as well as in HC [41]. However, although this
appears to be the case across the brain, it may not apply
at regional levels. This is the likely reason we did not
find a gender effect in our hippocampal meta-regression.
Previous evidence revealed that in different brain regions
are different in male and female not only in MCI but also
in HC. For example, atrophy rates for the thalamus,
caudate nucleus, and right middle temporal gyrus are
higher in male MCI, compared with female, and atrophy
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higher in female MCI than male [42]. Our finding that
APOE ε4 genotype is a significant moderator and is asso-
ciated with a higher rate of hippocampal atrophy in MCI
is consistent with reviewed longitudinal studies that were
not included in the meta-analysis. Moreover, the effect ap-
pears to become more salient across the disease process
with MCI and AD showing that the APOE ε4 genotype
is associated with faster atrophy rates [43,44],
particularly in the hippocampus [45,46]. Association
between APOE ε4 genotype and greater atrophy rate has
been reported previously in HC [47]. Thus, all parts of
the brain do not seem to have a similar vulnerability to
the effect of APOE ε4 genotype and brain areas primarily
involved in AD pathology, i.e., medial temporal lobe and
particularly the hippocampus, are more affected, although
the pattern of vulnerability is disease-stage specific
[48,49]. APOE ε4 genotype is also associated with
lower level of b-amyloid [50] and higher level of total
and phosphorylated tau proteins [49] in cerebrospinal
fluid. All these biomarkers are shown to be associated
with faster regional brain atrophy (particularly the hippo-
campus) together and separately [48–52].4.5. Strength and limitations of the study
A broad search of the literature (e.g., using a wide range
of search terms) and inclusion of all available studies (using
all sorts of structural measurements) were major strengths of
this review. Special care was taken to combine studies with
compatible measurements—to investigate pooled estimates
of atrophy rates—and an attempt was made to comprehen-
sively integrate incompatible findings and to summarize
available knowledge about structural changes in MCI pa-
thology. However, the review was limited by a relatively
small number of available studies that could be included
in the meta-analyses, particularly where whole brain and en-
torhinal cortex analyses are concerned. Additionally, many
brain regions (such as the cerebellum) could not be analyzed
because of lack of evidence and should be the focus of future
studies. In addition, owing to the small number of studies in
the meta-analysis, in relation to the number of moderators, it
was recognized that estimates of moderator effects might
be imprecise. The review was limited to comparing stable
HC and prevalent MCI and data related to healthy partici-
pants converting to MCI and MCI participants converting
to AD were insufficient to consider them in the present
investigation.5. Conclusion
To our knowledge, this is the first systematic review of
longitudinal studies investigating MCI-related brain struc-
tural changes. The analyses revealed that the whole brain
shrinks approximately two times faster in MCI participants
compared with matched healthy people of the same age.Additionally, the medial temporal lobe regions—particu-
larly the entorhinal cortex and hippocampus—are remark-
ably affected in AD pathology and associated with risk
factors including APOE ε4 genotype and female gender.
These regions demonstrate an atrophy rate of 1.5–2.2%/
year times for MCI compared with HC. Although the medial
temporal lobe was reported as the region highly involved in
AD-related neurodegeneration, estimated atrophy rates in
this region do not convincingly explain the amount of annual
whole brain volume loss observed inMCI. Further investiga-
tion of other components of neural tissue, including white
matter and non-neural brain tissue (e.g., connective tissue),
is needed.
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1. Systematic review: The authors reviewed literature
investigating longitudinal structural brain changes
in mild cognitive impairment (MCI). Studies largely
investigated the preclinical phase of Alzheimer’s dis-
ease andmostly focused on the medial temporal lobe.
2. Interpretation: In MCI, our analyses revealed a mean
shrinkage of 5 mL/year in the whole brain above
normal aging. Hippocampus and entorhinal cortex
contributed less than 1.5% to the whole brain volume
loss. Gray matter atrophy reported for other parts of
the brain cannot explain a 5-mL annual whole brain
volume loss. Atrophy in posterior parts of the brain
(including the cerebellum) have been largely un-
studied and may be important for explaining total
annual volume loss in MCI.
3. Future directions: This review proposes a framework
for generation of new studies regarding (1) atrophy
rates specific to the cerebellum and white matter in
MCI (2) and the role of non-neuronal brain tissue
(i.e. connective tissue) changes in MCI pathology.
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